WHAT IS TAXOTERE?
Taxotere was released in the United States in 1996 and is the most prescribed chemotherapy drug to treat breast cancer. It is manufactured by Sanofi-Aventis and was originally approved by the FDA in 1996. Approximately 3 million women in the United States are living with breast cancer and oncologists use Taxotere to treat about 75 percent of these cases.
Taxotere stops cells from dividing and multiplying. Healthy cells normally stop dividing when they are around other healthy cells. On the contrary, cancer cells do not have the ability to stop dividing which is how cancer continues to spread. Taxotere is used to attack cancer cells and stop growth.
GEICAM 9805 Trial Study (2005)
The New England Journal of Medicine published the study on December 2nd, 2010. The data revealed that 9.2% of cancer patients given Taxotere reported permanent hair loss. The GEICAM 9805 study evaluated 1,060 patients.
FOOD & DRUG ADMINISTRATION (FDA)
Food and Drug Administration (FDA) orders manufacturer Sanofi-Aventis to update chemotherapy drug Taxotere's warning label to include risks for permanent hair loss or alopecia. The label update was approved on December 11th, 2015.
June 20th, 2014
The FDA releases a Drug Safety Communication warning that chemotherapy drug docetaxel contains ethanol, which may cause patients to experience intoxication or drunk like symptoms.
April 16th, 2009
FDA sends a letter to Sanofi-Aventis warning the company their claim that Taxotere works better than competitor Taxol was false and was considered Misbranding, a federal crime.
The most significant complication women are experiencing is permanent Alopecia, otherwise referred to as permanent baldness. Chemotherapy is synonymous with hair loss, though most cases resolve themselves within 3-6 months after completion of treatment. Alopecia is irreversible and can happen anywhere on a woman's body.
TAXOTERE LAWSUIT UPDATES
MDL 2740: October 4th, 2016
Judge: Kurt D. Engelhardt
Venue: Eastern District of Louisiana
Pending Actions: 1,272
September 24th, 2018
January 28th, 2019
April 8th, 2019
July 15th, 2019
November 4th, 2019